Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01789333
Other study ID # AAAF4157
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date September 1, 2010
Est. completion date December 30, 2022

Study information

Verified date February 2023
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to see if brighter lights will allow for shortening of the treatment time required to stabilize the eyes of patients with keratoconus or a bulging cornea. The investigators will be comparing the therapeutic effects of two different higher brightnesses of ultra violet light on a riboflavin treated eye. One light will be twice as bright as the other and the exposure time of these brighter lights to deliver equivalent energy to the cornea will be reduced from the standard 30 minutes to 10 and 5 minutes. Riboflavin is vitamin B2 and the investigators are trying to determine if an identical clinical effect can be achieved the brighter treatment lights are used for shorter times. The investigators will also monitor the clinical effect and the status of the cornea to see if additional risks are associated with the brighter light.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 30, 2022
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: Subjects who have one or both eyes that meet two of the following criteria will be considered candidates for this study: 1. 16 years of age or older 2. Having a diagnosis of progressive keratoconus or pellucid marginal degeneration. 1. Characteristic pattern of deformity as analyzed by the Pentacam map. 2. Minimal thickness of 350 microns 3. The ability to sign a written informed consent 4. States a willingness and ability to comply with schedule for follow-up visits 5. Subject willing to remove contact lenses prior to evaluation and treatment Inclusion criteria for ectasia 1. History of having undergone a keratorefractive procedure and show: 1. Steepening by Pentacam study 2. Thinning of cornea 3. Shift in the position of thinnest portion of cornea 4. Unstable refraction with increasing myopia and astigmatism 5. Development of irregular astigmatism 2. At least two of the above criteria must be present. Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from this study: Subjects meeting any of the following criteria will be excluded from this protocol: 1. Eyes classified as either normal or atypical normal, 2. Corneal pachymetry = 350 microns at the thinnest point in treatment zone measured by Pentacam. 3. A history of delayed epithelial healing. 4. Pregnancy (including plan to become pregnant) or lactation during the course of the study 5. A known sensitivity to study medications 6. Patients with nystagmus or any other condition that is severe enough to prevent steady gaze during the treatment 7. Inability to cooperate with diagnostic tests. 8. Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing. 9. Patients who are unable to remain supine and tolerate a lid speculum.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
UVA Light with irradiance exposure of 9 mW/cm2
The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking. The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes).
Drug:
Riboflavin 0.1% ophthalmic solution
The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed. During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin).

Locations

Country Name City State
United States Edward Harkness Eye Institute-Columbia University Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Stephen Trokel

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Total Optical Aberrations of the Cornea following Cross-Linking Assessment of changes in corneal curvature, as analyzed using a Pentacam Scheimpflug Analyzer will be used in all patients. This allows measurement of corneal thickness, maximum and minimum curvatures and aberration analysis of the cornea as an optical element. The most significant objective measure of change is the total Higher Order Aberrations of the cornea and the Kmax, or steepest curvature of the cornea. Analysis of corneal curvature is directly related to improvement in the corneal shape which is directly related to visual function. Baseline to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04570020 - Scleral Lens Fitting Using Wide-Field OCT
Recruiting NCT02921009 - McNeel Eye Center Corneal Crosslinking Study N/A
Completed NCT01691651 - Botulinum Toxin A for the Treatment of Keratoconus N/A
Terminated NCT02762253 - Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus. Phase 2
Completed NCT01527708 - Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas N/A
Completed NCT01527721 - Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus N/A
Recruiting NCT00841386 - Treatment of Keratoconus Using Collagen Cross-Linking Phase 2/Phase 3
Completed NCT00347074 - A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients N/A
Completed NCT03187912 - Accelerated Corneal Cross-linking With Different Riboflavin Solutions Phase 3
Completed NCT00584285 - Corneal Topographer Fluorescein Patterns
Completed NCT03511495 - Reliability of Topography Measurements in Keratoconus
Not yet recruiting NCT05395650 - Cyanocobalamin as Photosensitizing Agent
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT03235856 - Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE
Completed NCT05019768 - Topo-pachimetric Accelerated Epi-On Cross-linking Compared to Dresden Protocol Using Riboflavin With Vitamin E TPGS N/A
Completed NCT05114928 - Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.
Completed NCT03647046 - Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus N/A
Recruiting NCT04439552 - fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
Recruiting NCT06100939 - Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus Phase 3
Completed NCT02444923 - Scleral Versus Corneal RGP Contact Lenses in Irregular Cornea Disorders N/A